Avstera Therapeutics Corp.
Tuesday, June 04, 2024
Oncology
Company Presentation Theater 1
Avstera Therapeutics is an oncology-focused biotech company headquartered in the Philadelphia area dedicated to address the large disease burden and significant unmet need of advanced cancer patients. With a focus on foundational tumor biology science, Avstera leverages cutting edge approaches to tackle key immunological challenges seen in the tumor microenvironment, such as the modulation of immunosuppressive macrophages. Avstera's lead program is an orally bioavailable, highly selective HDAC6i which is in Phase I.
Company Website:
http://www.avstera.com
Lead Product in Development:
AVS100 - Highly Selective Oral HDAC6 Inhibitor Targeting Locally Advanced or Metastatic Solid Tumors
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Company HQ City
Malvern
Company HQ State
PA
Company HQ Country
United States
CEO/Top Company Official
Karthik Musunuri
Development Phase of Primary Product
Phase I
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())